Alkermes Logo
IE00B56GVS15
A1JKVH
ALKS

Alkermes

Prognose

Analytikernes gennemsnitlige kursmål er 53,50 € (+30,58 %). Medianen er 53,31 € (+30,12 %).

Køb
  16
Behold
  10
Sælg
  3

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Alkermes CCO sells 7,576 shares for $373,000 under 10b5-1 plan

    Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes, sold 7,576 shares on Aug. 17, 2026 for a weighted average price of $49.23, netting about $373,000. The sale was executed under a Rule 10b5-1 trading plan adopted May 15, 2026 and reduced his direct holdings to 102,193 shares (≈0.06% ownership). The company reported strong H1 2026 revenue growth and a 12-month stock gain, and analysts remain generally positive on Alkermes. » Mere på finance.yahoo.com


  • Alkermes reports positive Phase‑2 data for narcolepsy drug Alixorexton

    Alkermes published Phase‑2 data from the Vibrance‑1 study in 92 adults with narcolepsy type 1. Once‑daily doses of 4, 6 or 8 mg Alixorexton produced statistically significant improvements in excessive daytime sleepiness; all dose groups achieved mean Maintenance of Wakefulness Test values of at least 20 minutes and Epworth scores of ≤10 at week 6. In the 6‑mg group the weekly cataplexy rate fell versus placebo; the drug was generally well tolerated and no serious adverse events occurred. Based on these results, a global Phase‑3 program (Brilliance Studies) is now under way; Alixorexton has received Breakthrough Therapy and Orphan Drug status in the US for certain indications. » Mere på de.investing.com


  • Alkermes cuts interest margins for senior term loans

    Alkermes has agreed an amendment to its loan agreement that reduces the interest margins on its secured senior term loans. The adjustment lowers the margin on the TLA facility by 0.75 percentage points and on the TLB facility by 0.50 percentage points; TLA has an outstanding amount of USD 745.3m (maturity Feb. 12, 2031), TLB USD 773.1m (maturity Aug. 12, 2031). After the amendment, TLA will bear interest at Term SOFR plus 1.75–2.25% or Alternate Base Rate plus 0.75–1.25% depending on net leverage, and TLB at Term SOFR plus 2.25% or Alternate Base Rate plus 1.25%. The agreement was made with several lenders, including JPMorgan Chase and BofA Securities as arrangers. » Mere på de.investing.com


  • Alkermes cuts full-year forecast despite strong Q2, stock falls premarket

    Alkermes beat expectations in Q2 2026 with adjusted EPS of $0.00 and revenue of $496 million (+27% y/y), but was weighed down by a 2026 revenue forecast of $1.785 billion that missed the analyst consensus. The stock fell about 5.2% premarket to $50.00 as investors took profits after a strong rally year-to-date. Narcolepsy drug LUMRYZ contributed significantly to revenue, but integration costs and the muted outlook clouded sentiment. Piper Sandler raised its price target to $65 and reiterated “Overweight,” but that did not halt the short-term decline. » Mere på de.investing.com


  • Alkermes hits 52-week high of $55.28 after positive trial data

    Alkermes’ stock climbed to a 52-week high of $55.28 and is trading near that level, with a year-to-date return of about 95%. The company reported positive Phase 2 data from the Alixorexton study VIBRANCE-2, prompting several analysts to raise price targets (Needham $54, Mizuho $65), while BofA moved to underperform on valuation concerns (target $38). The stock shows a high gross margin of 87%, but technical indicators like the RSI point to possible overbought conditions. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Alkermes en omsætning på 423,88 mio. € og et nettoresultat på 14,38 mio. €

(EUR) september 2026
YoY
Omsætning 423,88 mio. 26,19 %
Bruttofortjeneste 340,7 mio. 16,71 %
Nettoresultat 14,38 mio. 79,61 %
EBITDA 61,31 mio. 33,88 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
7,1 mia. €
Antal aktier
168,04 mio.
Højeste/laveste i 52 uger
50,73 € - 24,61 €
Udbytte Nej
Beta
0,27
P/E (PE Ratio)
15.445,00
PEG (PEG Ratio)
-154,67
K/I (PB Ratio)
4,17
P/S (PS Ratio)
4,44

Virksomhedsprofil

Alkermes plc er et biofarmaceutisk selskab, der forsker i, udvikler og kommercialiserer lægemidler for at imødekomme patienters uopfyldte medicinske behov inden for forskellige terapeutiske områder i USA, Irland og internationalt. Selskabets markedsførte produkter omfatter ARISTADA, en intramuskulær injicerbar suspension til behandling af skizofreni; VIVITROL til behandling af alkoholafhængighed og forebyggelse af opioidafhængighed; RISPERDAL CONSTA til behandling af skizofreni og bipolar I-lidelse; INVEGA SUSTENNA til behandling af skizofreni og skizoaffektiv lidelse; XEPLION, INVEGA TRINZA og TREVICTA til behandling af skizofreni og skizoaffektiv lidelse; samt VUMERITY til behandling af tilbagevendende former for multipel sklerose hos voksne, herunder klinisk isoleret syndrom, relapsing-remitting og aktiv sekundær progredierende sygdom. Selskabet udvikler også LYBALVI, en oral atypisk antipsykotisk lægemiddelkandidat til behandling af voksne med skizofreni og bipolar I-lidelse; og nemvaleukin alfa, et konstrueret fusionsprotein til at udvide tumordræbende immunceller og undgå aktivering af immunsuppressive celler. Selskabet har samarbejdsaftaler primarily med Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc. og Janssen Pharmaceutica International. Alkermes plc blev grundlagt i 1987 og har hovedkontor i Dublin, Irland.

Navn
Alkermes
CEO
Blair Jackson
Hjemsted Dublin, du
Irland
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
16.07.1991
Medarbejdere 2.050

Tickersymboler

Børs Symbol
NASDAQ
ALKS
Frankfurt
8AK.F
SIX
8AK.SW
München
8AK.MU
🍪

Parqet  bruger cookies. Læs mere